Indaptus Therapeutics receives Clinical Trial Authorization from Health Canada to expand its ongoing U.S. clinical trial INDP-D101 for its lead cancer immunotherapy candidate Decoy20.
Incyte anticipates a transformational 2025 with multiple potential drug launches and pivotal trial readouts across its oncology and inflammation & autoimmunity portfolio.
Indaptus Therapeutics reported a 26% decrease in operating expenses for Q3 2024, driven by the completion of certain manufacturing processes for Decoy20.
Indaptus Therapeutics and BeiGene have entered a clinical supply agreement to evaluate the combination of Decoy20 and tislelizumab in cancer treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.